From Busboy to Brain Scientist with Dr. Benjamin Hoehn 

Dr Benjamin Douglass Hoehn joined Annexon biosciences as Sr Dir of clinical development in July 2021. He has over 15 years of in-depth experience in the biopharmaceutical and medical device industry, including global research and development, clinical operations, business development, and consulting, he spent time working for companies in Asia Pacific, Europe, North America and starting his own consulting business. Having trained as a neurosurgeon prior to entering industry, Dr. Hoehn has focused on interventions into acute and chronic neurodegenerative diseases such as Stroke, ALS, GBS, Parkinson’s, and Huntington disease. While at Kyowa Kirin was involved in the development and launch of Istradefylline in the United States, the first novel therapy for Parkinson’s in over 15 years. He previously served as CMO for Johnson and Johnson Codman Neuro division, and global lead for Clinical Development at UCB. It was at UCB that Dr. Hoehn began his work with complement inhibitors leading the Zilucoplan mission which included Myasthenia gravis, IMNM, and ALS. Currently at Annexon, he continues his work with complement-based therapies leading clinic development for ALS, Huntington Disease and GBS indications. Dr Hoehn earned his M.D. and PhD in neuroscience from Stanford University and trained in Neurosurgery at the University of Virginia.